STAAR Surgical (NASDAQ:STAA) Price Target Cut to $16.00 by Analysts at Wells Fargo & Company

STAAR Surgical (NASDAQ:STAA) had its price target cut by Wells Fargo & Company from $30.75 to $16.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have an equal weight rating on the medical instruments supplier’s stock.

STAA has been the subject of a number of other research reports. Wedbush initiated coverage on shares of STAAR Surgical in a report on Tuesday, February 3rd. They issued a “neutral” rating and a $26.00 price target for the company. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of STAAR Surgical in a report on Thursday, January 22nd. Canaccord Genuity Group decreased their price target on STAAR Surgical from $30.75 to $22.00 and set a “hold” rating on the stock in a research note on Thursday, January 15th. Finally, Stifel Nicolaus lowered their price target on STAAR Surgical from $19.00 to $18.00 and set a “hold” rating on the stock in a report on Wednesday. One investment analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, STAAR Surgical presently has an average rating of “Reduce” and a consensus price target of $18.94.

STAAR Surgical Price Performance

STAA opened at $18.57 on Thursday. STAAR Surgical has a 12 month low of $14.69 and a 12 month high of $30.81. The stock has a market capitalization of $923.71 million, a P/E ratio of -11.39 and a beta of 1.05. The business has a 50 day simple moving average of $19.78 and a 200-day simple moving average of $24.12.

STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings data on Tuesday, March 3rd. The medical instruments supplier reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.51). STAAR Surgical had a negative return on equity of 10.03% and a negative net margin of 33.60%.The business had revenue of $57.80 million for the quarter, compared to analyst estimates of $75.54 million. The firm’s revenue was up 18.0% compared to the same quarter last year. Research analysts anticipate that STAAR Surgical will post -1.14 EPS for the current year.

Insider Activity

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 27,485 shares of STAAR Surgical stock in a transaction on Friday, January 9th. The shares were bought at an average price of $22.05 per share, with a total value of $606,044.25. Following the completion of the acquisition, the insider directly owned 15,453,629 shares of the company’s stock, valued at approximately $340,752,519.45. This trade represents a 0.18% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 434,138 shares of company stock valued at $9,424,176 over the last quarter. 0.59% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of STAA. CWM LLC grew its holdings in STAAR Surgical by 74.1% during the 2nd quarter. CWM LLC now owns 1,563 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 665 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of STAAR Surgical by 2,605.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 1,016 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of STAAR Surgical by 61.4% in the third quarter. GAMMA Investing LLC now owns 1,856 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 706 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of STAAR Surgical by 691.0% in the second quarter. PNC Financial Services Group Inc. now owns 3,607 shares of the medical instruments supplier’s stock valued at $61,000 after acquiring an additional 3,151 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of STAAR Surgical by 375.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 4,673 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

STAAR Surgical News Roundup

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: Management said it is targeting a return to profitability in 2026 and highlighted recovery plans after a volatile year—this gives investors a potential multi-quarter path to improvement. STAAR Surgical Eyes 2026 Profit
• Positive Sentiment: Earnings commentary noted strong sales growth in China, which supports revenue momentum in a key market even though overall results disappointed. Q4 Highlights: China Growth
• Neutral Sentiment: Several brokers maintained Hold/Neutral ratings (Canaccord $22 PT; Needham still neutral), signaling cautious investor stance rather than outright sell recommendations. Canaccord Hold Needham Hold
• Neutral Sentiment: The full Q4 earnings call transcript is available for investors who want detail on drivers, margins and the company’s remediation steps. Earnings Call Transcript
• Negative Sentiment: Wells Fargo sharply cut its price target from $30.75 to $16 and moved to an Equal Weight rating—this large downgrade adds selling pressure and signals lowered expectations for near-term recovery. Wells Fargo PT Cut
• Negative Sentiment: Stifel trimmed its price target to $18 and kept a Hold, another downward revision following noisy Q4 results that reinforces caution. Stifel PT Cut
• Negative Sentiment: Q4 results missed estimates (reported EPS -$0.37 vs. consensus ~$0.14; revenue ~$57.8M vs. est. ~$75.5M) and showed a negative net margin—these misses are the primary catalyst for the downgrades and the near?term share weakness. Q4 Results

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.